{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:54:15Z","timestamp":1780408455470,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Seit mehr als 10\u00a0Jahren ist Disulfiram in Deutschland nicht mehr zugelassen. Dennoch wird es seitens einer Reihe von Ambulanzen psychiatrischer Fachkliniken sowie niedergelassener \u00c4rzte weiter off-label eingesetzt. Diese haben sich 2018 zum \u201eNetzwerk alkoholaversive Pharmakotherapie\u201c (NAP) zusammengeschlossen, um die Qualit\u00e4t dieser Behandlungsform aufrechtzuhalten.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ziel der Arbeit<\/jats:title>\n            <jats:p>Beschreibung des gegenw\u00e4rtigen Behandlungsumfangs, der Patientencharakteristika, der Nebenwirkungen und der begleitenden Therapieangebote der Behandlung mit Disulfiram.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>Seit 2019 f\u00fchrt das NAP in den beteiligten Zentren j\u00e4hrlich eine retrospektive Erhebung zu oben genannten Parametern durch.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse<\/jats:title>\n            <jats:p>Im Zeitraum von 2019 bis 2023 wurden durch 33\u00a0Zentren zusammen 1579 Behandlungsf\u00e4lle erfasst. Bei 152 Patienten wurden insgesamt 241 Trinkereignisse beschrieben, von denen 26\u00a0zu station\u00e4rer Behandlung ohne Komplikationen oder anhaltende Gesundheitssch\u00e4den f\u00fchrten. H\u00e4ufigste Nebenwirkungen waren in absteigender Reihenfolge K\u00f6rpergeruch (2,5\u202f%), M\u00fcdigkeit, m\u00e4nnliche sexuelle Funktionsst\u00f6rungen, benigner Transaminasenanstieg, allergische Hautreaktionen und Polyneuropathie (0,8\u202f%). \u00dcber ein Viertel der Patienten litt komorbid an Depressionen und je ca.\u00a05\u202f% an ADHS, emotional instabilen bzw. anderen Pers\u00f6nlichkeitsst\u00f6rungen, Traumafolgest\u00f6rungen sowie Angstst\u00f6rungen. 33\u202f% der Patienten wurden mit Antidepressiva und 12\u202f% mit sedierenden Antipsychotika behandelt. Begleitende Gruppentherapien wurden bei 66\u202f% der Patienten angeboten.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diskussion<\/jats:title>\n            <jats:p>Die Behandlung mit Disulfiram ist legal m\u00f6glich, allgemein gut vertr\u00e4glich und sicher. Sie wird in den meisten Behandlungszentren als Bestandteil eines Gesamtbehandlungsplanes angeboten, der eine multimodale Behandlung komorbider psychiatrischer Erkrankungen miteinschlie\u00dft.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00115-024-01714-5","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:24:34Z","timestamp":1724423074000},"page":"159-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patienten- und Qualit\u00e4tsmerkmale bei der Behandlung mit Disulfiram (\u201eAntabus\u201c) im deutschsprachigen \u201eNetzwerk alkoholaversive Pharmakotherapie\u201c","Patient and quality characteristics in the treatment with disulfiram (Antabus) in the German \u201cNetwork for Alcohol Aversive Pharmacotherapy\u201d"],"prefix":"10.1007","volume":"96","author":[{"given":"Ulrich S.","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Plickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"L\u00fcdecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Stuppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rosenbeiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Krisam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Scholz-Hehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Havemann-Reinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Wedekind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Luderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Spreer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"1714_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/ADM.0000000000000992","volume":"16","author":"A Bahji","year":"2022","unstructured":"Bahji\u00a0A, Bach\u00a0P, Danilewitz\u00a0M et\u00a0al (2022) Pharmacotherapies for Adults With Alcohol Use Disorders: A\u00a0Systematic Review and Network Meta-analysis. J\u00a0Addict Med 16:630\u2013638. https:\/\/doi.org\/10.1097\/ADM.0000000000000992","journal-title":"J Addict Med"},{"key":"1714_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jhep.2005.12.016","volume":"44","author":"E Bj\u00f6rnsson","year":"2006","unstructured":"Bj\u00f6rnsson\u00a0E, Nordlinder\u00a0H, Olsson\u00a0R (2006) Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J\u00a0Hepatol 44:791\u2013797. https:\/\/doi.org\/10.1016\/j.jhep.2005.12.016","journal-title":"J Hepatol"},{"key":"1714_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/FTD.0b013e31822fbf7c","volume":"33","author":"S Br\u00fcnen","year":"2011","unstructured":"Br\u00fcnen\u00a0S, Vincent\u00a0PD, Baumann\u00a0P et\u00a0al (2011) Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a\u00a0therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit 33:561\u2013572. https:\/\/doi.org\/10.1097\/FTD.0b013e31822fbf7c","journal-title":"Ther Drug Monit"},{"key":"1714_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-32-9876-7","volume-title":"Disulfiram: Its Use in Alcohol Dependence and Other Disorders","author":"A De Sousa","year":"2019","unstructured":"De Sousa\u00a0A (2019) Disulfiram: Its Use in Alcohol Dependence and Other Disorders https:\/\/doi.org\/10.1007\/978-981-32-9876-7"},{"key":"1714_CR5","volume-title":"S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener St\u00f6rungen","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.\u202fV. (DGPPN), Dt. Ges. f. Suchtforschung u.\u00a0Suchttherapie e.\u202fV. (DG-Sucht)","year":"2020","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.\u202fV. (DGPPN), Dt. Ges. f. Suchtforschung u.\u00a0Suchttherapie e.\u202fV. (DG-Sucht) (2020) S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener St\u00f6rungen (Aktualisierte Version 2020)"},{"key":"1714_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2796.1992.tb00562.x","volume":"232","author":"H Friis","year":"1992","unstructured":"Friis\u00a0H, Andreasen\u00a0PB (1992) Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J\u00a0Intern Med 232:133\u2013138. https:\/\/doi.org\/10.1111\/j.1365-2796.1992.tb00562.x","journal-title":"J Intern Med"},{"key":"1714_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s00115-015-4339-0","volume":"87","author":"K Hochsattel","year":"2016","unstructured":"Hochsattel\u00a0K, Brieger\u00a0P (2016) Disulfiram in der ambulanten Therapie alkoholabh\u00e4ngiger Menschen. Nervenarzt 87:506\u2013512. https:\/\/doi.org\/10.1007\/s00115-015-4339-0","journal-title":"Nervenarzt"},{"key":"1714_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1024\/0939-5911.a000281","volume":"59","author":"F Kiefer","year":"2013","unstructured":"Kiefer\u00a0F, Preu\u00df\u00a0U (2013) Nachrichten aus der DG-Sucht. Sucht 59:373\u2013373. https:\/\/doi.org\/10.1024\/0939-5911.a000281","journal-title":"Sucht"},{"key":"1714_CR9","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.2174\/138161210791516431","volume":"16","author":"H Krampe","year":"2010","unstructured":"Krampe\u00a0H, Ehrenreich\u00a0H (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. curr pharm des 16:2076\u20132090. https:\/\/doi.org\/10.2174\/138161210791516431","journal-title":"Curr Pharm Des"},{"key":"1714_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1530-0277.2006.00013.x","volume":"30","author":"H Krampe","year":"2006","unstructured":"Krampe\u00a0H, Stawicki\u00a0S, Wagner\u00a0T et\u00a0al (2006) Follow-up of 180 alcoholic patients for up to 7\u00a0years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 30:86\u201395. https:\/\/doi.org\/10.1111\/j.1530-0277.2006.00013.x","journal-title":"Alcohol Clin Exp Res"},{"key":"1714_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1055\/s-0042-106076","volume":"17","author":"M Luderer","year":"2016","unstructured":"Luderer\u00a0M, Koopmann\u00a0A, Hoffmann\u00a0S et\u00a0al (2016) Verbessert eine intensivierte ambulante Behandlung das Outcome von schwer alkoholabh\u00e4ngigen Patienten? Eine Pilotstudie. Suchttherapie 17:175\u2013180. https:\/\/doi.org\/10.1055\/s-0042-106076","journal-title":"Suchttherapie"},{"key":"1714_CR12","volume-title":"CRA-Manual zur Behandlung von Alkoholabh\u00e4ngigkeit: erfolgreicher behandeln durch positive Verst\u00e4rkung im sozialen Bereich","author":"RJ Meyers","year":"2017","unstructured":"Meyers\u00a0RJ, Smith\u00a0JE (2017) CRA-Manual zur Behandlung von Alkoholabh\u00e4ngigkeit: erfolgreicher behandeln durch positive Verst\u00e4rkung im sozialen Bereich, 2017.\u00a0Aufl. Bd. 5. Psychiatrie Verlag, K\u00f6ln","edition":"2017"},{"key":"1714_CR13","unstructured":"Nycomed (2007) Fachinformation Antabus\u00ae Dispergetten."},{"key":"1714_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41598-018-19577-7","volume":"8","author":"S Reinhardt","year":"2018","unstructured":"Reinhardt\u00a0S, Stoye\u00a0N, Luderer\u00a0M et\u00a0al (2018) Identification of disulfiram as a\u00a0secretase-modulating compound with beneficial effects on Alzheimer\u2019s disease hallmarks. Sci Rep 8:1329. https:\/\/doi.org\/10.1038\/s41598-018-19577-7","journal-title":"Sci Rep"},{"issue":"2","key":"1714_CR15","first-page":"47","volume":"16","author":"S R\u00f6sner","year":"2014","unstructured":"R\u00f6sner\u00a0S, Grosshans\u00a0M, Mutschler\u00a0J (2014) Disulfiram: Aktuelle Befundlage und Wirkmechanismen. Suchtmed 16(2):47\u201352","journal-title":"Suchtmed"},{"key":"1714_CR16","doi-asserted-by":"publisher","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","volume":"9","author":"MD Skinner","year":"2014","unstructured":"Skinner\u00a0MD, Lahmek\u00a0P, Pham\u00a0H, Aubin\u00a0H\u2011J (2014) Disulfiram Efficacy in the Treatment of Alcohol Dependence: A\u00a0Meta-Analysis. Plos One 9:e87366. https:\/\/doi.org\/10.1371\/journal.pone.0087366","journal-title":"Plos One"},{"key":"1714_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/WNF.0000000000000050","volume":"37","author":"M Specka","year":"2014","unstructured":"Specka\u00a0M, Heilmann\u00a0M, Lieb\u00a0B, Scherbaum\u00a0N (2014) Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment. Clin Neuropharmacol 37:161\u2013165. https:\/\/doi.org\/10.1097\/WNF.0000000000000050","journal-title":"Clin Neuropharmacol"},{"key":"1714_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1055\/s-0033-1341439","volume":"14","author":"M Stuppe","year":"2013","unstructured":"Stuppe\u00a0M, Froesa\u00a0G, Pinzke\u00a0R (2013) Community Reinforcement Approach in einer psychiatrischen Klinik. Suchttherapie 14:56\u201363. https:\/\/doi.org\/10.1055\/s-0033-1341439","journal-title":"Suchttherapie"},{"key":"1714_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1055\/a-1221-2727","volume":"15","author":"U Zimmermann","year":"2021","unstructured":"Zimmermann\u00a0U, Spreer\u00a0M (2021) SOP Ambulante Alkoholaversionstherapie mit Disulfiram. Psych Up2date 15:364\u2013369. https:\/\/doi.org\/10.1055\/a-1221-2727","journal-title":"Psych Up2date"},{"key":"1714_CR20","unstructured":"Zeitgem\u00e4\u00dfe Alkohol-Aversionstherapie mit Disulfiram | Prof. Dr. Ulrich Zimmermann. https:\/\/youtu.be\/9sVzJ5RMjcU"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01714-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:47:26Z","timestamp":1741002446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01714-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01714-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"28 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Zimmermann erhielt Vortragshonorare von Takeda Pharma, Amomed Pharma, Ameos Gruppe, Therapieverbund Ludwigsm\u00fchle, Sch\u00f6n Kliniken, Akademie im Park Wiesloch, Universit\u00e4tsklinikum Regensburg und ist als Berater f\u00fcr die Firma Axunio Pharma t\u00e4tig. M.\u00a0Luderer erhielt Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeit von Takeda Pharma, MEDICE, Idorsia, Recordati, Akademie im Park Wiesloch, DGPPN e.\u202fV., Honorare f\u00fcr Autorent\u00e4tigkeit von Thieme und Elsevier sowie eine Aufwandsentsch\u00e4digung f\u00fcr die T\u00e4tigkeit als Drogen- und Suchtbeauftragter f\u00fcr Berufsangeh\u00f6rige der Landes\u00e4rztekammer Hessen. D.\u00a0Wedekind erhielt Beratungshonorare von Recordati Pharma. T.\u00a0Link erhielt Vortragshonorare von Akademie im Park Wiesloch, Baden-W\u00fcrttembergischer Landesverband f\u00fcr Pr\u00e4vention und Rehabilitation gGmbH, Parit\u00e4tische Akademie S\u00fcd gGmbH, SRH Berufliches Trainingszentrum Wiesloch, W\u00fcrtt. Verwaltungs- und Wirtschafts-Akademie e.\u202fV., Heidelberger Institut f\u00fcr Tiefenpsychologie, KV Baden-W\u00fcrtt. und KWBW Verbundweiterbildung sowie Aufwandsentsch\u00e4digung f\u00fcr die T\u00e4tigkeit im Ausschuss Suchtmedizin der Landes\u00e4rztekammer Baden-W\u00fcrtt. C.\u00a0Plickert, C.\u00a0L\u00fcdecke, M.\u00a0Stuppe, C.\u00a0Rosenbeiger, Y.\u00a0Krisam, J.\u00a0Keller, G.\u00a0B\u00fchler, D.\u00a0Scholz-Hehn, U.\u00a0Havemann-Reinecke und M.\u00a0Spreer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}